Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
Medtronic (MDT) Progresses in SNM With Updated InterStim Label
by Zacks Equity Research
Medtronic (MDT) expects this updated labeling with wider procedural options and shorter wait time to improve patient access to MRI exams and add more flexibility for MRI providers.
Protect Your Portfolio From Volatility With 5 Low-Beta Picks
by Nalak Das
At this stage, it is prudent to invest in low-beta stocks with a favorable Zacks Rank as these will be less volatile than the broader market. These are: ABT, CAT, CNA, GOLF and SAFM.
OPKO Health (OPK) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
OPKO Health's (OPK) fourth-quarter results benefit from strength in diagnostics.
Top Analyst Reports for Abbott, SAP & Freeport-McMoRan
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), SAP SE (SAP), and Freeport-McMoRan (FCX).
Medtronic's (MDT) Midas Rex Drills Completes First U.S. Surgery
by Zacks Equity Research
Medtronic's (MDT) recent surgeries reach a milestone in the transformation of spine surgery as a result of increased accuracy and minimally invasive technique.
Globus Medical (GMED) Q4 Earnings Beat, U.S. Business Strong
by Zacks Equity Research
Globus Medical's (GMED) spinal implant business performance varies by region in Q4.
Ecolab's (ECL) Certified Program to Build Customer Confidence
by Zacks Equity Research
Ecolab's (ECL) science-backed comprehensive program to help food retailers to support customer confidence.
Masimo (MASI) Announces Full Market RollOut of SafetyNet-OPEN
by Zacks Equity Research
Masimo (MASI) SafetyNet-OPEN aids organizations in detecting those who are most vulnerable to COVID-19.
Illumina (ILMN) Sequencing & Microarray Sales Hurt by Pandemic
by Zacks Equity Research
Seasonality in DTC functionality also continues to erode Illumina's (ILMN) microarray sales.
Henry Schein (HSIC) Q4 Earnings Top Estimates, Margins Dip
by Zacks Equity Research
Henry Schein (HSIC) sees robust segmental performance in Q4 boosted by strong rebound in sales, and solid demand for PPE and COVID-19-related products.
Bruker (BRKR) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Bruker's (BRKR) revenues increased 4.6% year over year to $627.5 million but declined 0.4% organically in fourth-quarter fiscal 2020.
Exact Sciences (EXAS) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Exact Sciences' (EXAS) legacy Screening business sees an uptick in revenues in Q4 earnings.
Here's Why You Should Hold on to McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from the multi-year strategic growth initiative and strength in the Distribution Solutions segment.
Zacks.com featured highlights include: Abbott Laboratories, Facebook, Stanley Black & Decker, Leidos and Euronet
by Zacks Equity Research
Zacks.com featured highlights include: Abbott Laboratories, Facebook, Stanley Black & Decker, Leidos and Euronet
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical
Ecolab (ECL) Q4 Earnings In Line With Estimates, Revenues Lag
by Zacks Equity Research
Although Ecolab's (ECL) fourth-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.
CVS Health (CVS) Q4 Earnings Top Estimates but Decline Y/Y
by Zacks Equity Research
The pandemic affects CVS Health's (CVS) fourth-quarter revenues in the Pharmacy Services segments as new therapy prescriptions reduce due to lower provider visits.
BD (BDX) Gets EUA, CE Mark for New Molecular Diagnostic Test
by Zacks Equity Research
BD's (BDX) new test has the capability to detect SARS-CoV-2 and Influenza A+B in a single test.
5 Top Ranked Stocks With Solid Sales Growth to Buy Right Now
by Swayta Shah
Sales growth is an important indicator of a company's health and ability to sustain its business. Let's check Abbott (ABT), Facebook (FB), Stanley Black & Decker (SWK), Leidos (LDOS) & Euronet (EEFT) as these might witness solid sales growth.
TeleFlex (TFX) Organic Sales Hit by COVID-19, Urolift Grows
by Zacks Equity Research
TeleFlex (TFX) Interventional business revenues are down due to the cancellation of certain non-emergent procedures.
Intersect ENT's (XENT) SDS With PROPEL Mini Now in U.S.
by Zacks Equity Research
Intersect ENT's (XENT) SDS, packaged with its PROPEL Mini Sinus Implant, is expected to boost the company's business following its U.S. availability.
DaVita (DVA) Q4 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
DaVita's (DVA) bottomline in Q4 declines year over year.
DexCom (DXCM) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth.
Zimmer (ZBH) Non-Core Arm Spinoff to Aid Amid COVID-19 Crisis
by Zacks Equity Research
In the Americas, there is increased pressure on Zimmer Biomet (ZBH) procedural volume as a result of surge in infections.
Bio-Rad (BIO) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Bio-Rad's (BIO) fourth-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.